Association of plasma brain-derived neurotrophic factor and cardiovascular risk factors and prognosis in angina pectoris

Biochemical and Biophysical Research Communications

Volumn 415, Issue 1, 2011, Pages 99-103

  Jiang, Hong ^a   Liu, Yan ^a   Zhang, Yun ^a   Chen, Zhe Yu ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angina pectoris; Brain derived neurotrophic factor; Coronary events; Risk factors

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT;

AGED; ANGINA PECTORIS; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS;

ANGINA;

EID: 80755140507     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.10.020     Document Type: Article

References (45)

1. Cohen M., Rentrop K.P. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: a prospective study. Circulation 1986, 74(3):469-476.
2. Meier P., Gloekler S., Zbinden R., et al. Beneficial effect of recruitable collaterals: a 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation 2007, 116(9):975-983.
3. Regieli J.J., Jukema J.W., Nathoe H.M., et al. Coronary collaterals improve prognosis in patients with ischemic heart disease. Int. J. Cardiol. 2009, 132(2):257-262.
4. Lewin G.R., Barde Y.A. Physiology of the neurotrophins. Annu. Rev. Neurosci. 1996, 19:289-317.
5. Donovan M.J., Lin M.I., Wiegn P., Ringstedt T., Kraemer R., Hahn R., et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 2000, 127(21):4531-4540.
6. Kermani P., Rafii D., Jin D.K., Whitlock P., Schaffer W., et al. Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors. J. Clin. Invest. 2005, 115:653-663.
7. Liu Y., Sun L., Huan Y., Zhao H., Deng J. Application of bFGF and BDNF to improve angiogenesis and cardiac function. J. Surg. Res. 2006, 136(1):85-91.
8. Yamamoto H., Gurney M.E. Human platelets contain brain-derived neurotrophic factor. J. Neurosci. 1990, 10:3469-3478.
9. Nakahashi T., Fujimara H., Altar C.A., Li J., Kambayashi J., et al. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett. 2000, 470:113-117.
10. Fujimura H., Altar C.A., Chen R., Nakamura T., Nakahashi T., Kambayashi J., Sun B., Tandon N.N. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb. Haemost. 2002, 87(4):728-734.
11. Manni L., Nikolova V., Vyagova D., Chaldakov G.N., Aloe L. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int. J. Cardiol. 2005, 102(1):169-171.
12. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998, 339:229-234.
13. Krabbe K.S., Nielsen A.R., Krogh-Madsen R., Plomgaard P., Rasmussen P., Erikstrup C., Fischer C.P., Lindegaard B., Petersen A.M., Taudorf S., Secher N.H., Pilegaard H., Bruunsgaard H., Pedersen B.K. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007, 50:431-438.
14. Krabbe K.S., Mortensen E.L., Avlund K., Pedersen A.N., Pedersen B.K., Jørgensen T., Bruunsgaard H. Brain-derived neurotrophic factor predicts mortality risk in older women. J. Am. Geriatr. Soc. 2009, 57(8):1447-1452.
15. Rossi G.P., Cesari M., Zanchetta M., Colonna S., Maiolino G., Pedon L., et al. The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J. Am. Coll. Cardiol. 2003, 41:930-937.
16. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur. Heart J. 2000, 21:1502-1513.
17. Grambsch P., Themeau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
18. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 2008, 27(2):157-172. (discussion 207-212).
19. Kerschensteiner M., Gallmeier E., Behrens L., Leal V.V., Misgeld T., Klinkert W.E., et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?. J. Exp. Med. 1999, 189:865-870.
20. Matthews V.B., Aström M.B., Chan M.H., Bruce C.R., Krabbe K.S., et al. Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP activated protein kinase. Diabetologia 2009, 52:1409-1418.
21. Teillon Sarah, Calderon German A, Rios Maribel Diminished diet-induced hyperglycemia and dyslipidemia and enhanced expression of PPARa and FGF21 in mice with hepatic ablation of brain-derived neurotropic factor. J. Endocrinol. 2010, 205:37-47.
22. Kishino A., Katayama N., Ishige Y., Yamamoto Y., Ogo H., Tatsuno T., Mine T., Noguchi H., Nakayama C. Analysis of effects and pharmacokinetics of subcutaneously administered BDNF. NeuroReport 2001, 12(5):1067-1072.
23. Yamamoto H., Gurney M.E. Human platelets contain brain-derived neurotrophic factor. J. Neurosci. 1990, 10(11):3469-3478.
24. Rosenfeld R.D., Zeni L., Haniu M., Talvenheimo J., Radka S.F., Bennett L., Miller J.A., Welcher A.A. Purification and identification of brain-derived neurotrophic factor from human serum. Protein Expr. Purif. 1995, 6(4):465-471.
25. Battinelli E.M., Markens B.A., Italiano J.E. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 2011, 118(5):1359-1369. (Epub 2011 June 16).
26. Iughetti L., Casarosa E., Predieri B., Patianna V., Luisi S. Plasma brain-derived neurotrophic factor concentrations in children and adolescents. Neuropeptides 2011, 45(3):205-211. (Epub 2011 March 21). 10.1016/j.npep.2011.02.00.
27. Lommatzsch M., Zingler D., Schuhbaeck K., Schloetcke K., Zingler C., et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol. Aging 2005, 26:115-123.
28. Bulló M., Peeraully M.R., Trayhurn P., Folch J., Salas-Salvadó J. Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women. Eur. J. Endocrinol. 2007, 157(3):303-310.
29. Sehgal S., Storrie B. Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release. J. Thromb. Haemost. 2007, 5(10):2009-2016.
30. Pepper M.S. Manipulating angiogenesis: from basic science to the bedside. Arterioscler. Thromb. Vasc. Biol. 1997, 17:605-619.
31. Henry T.D. Therapeutic angiogenesis. BMJ 1999, 318:1536-1539.
32. Kermani P., Rafii D., Jin D.K., Whitlock P., Schaffer W., Chiang A., Vincent L., Friedrich M., Shido K., Hackett N.R., Crystal R.G., Rafii S., Hempstead B.L. Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors. J. Clin. Invest. 2005, 115(3):653-663.
33. Aicher A., Heeschen C., Mildner-Rihm C., Urbich C., Ihling C., Technau-Ihling K., Zeiher A.M., Dimmeler S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 2003, 9(11):1370-1376.
34. Heeschen C., Lehmann R., Honold J., Assmus B., Aicher A., Walter D.H., Martin H., Zeiher A.M., Dimmeler S. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004, 109:1615-1622.
35. Dor Y., Djonov V., Keshet E. Induction of vascular networks in adult organs: implications to proangiogenic therapy. Ann. NY Acad. Sci. 2003, 995:208-216.
36. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275(5302):964-967.
37. Rafii S., Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 2003, 9:702-712.
38. Jain R.K., Duda D.G. Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell 2003, 3:515-516.
39. Carmeliet P., Luttun A. The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis. Thromb. Haemost. 2001, 86:289-297.
40. Losordo D.W., Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation 2004, 109:2692-2697.
41. Losordo D.W., Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part I: angiogenic cytokines. Circulation 2004, 109:2487-2491.
42. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A., Hajjar K.A., Manova K., Benezra R., Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7(11):1194-1201.
43. Heissig B., Hattori K., Dias S., Friedrich M., Ferris B., Hackett N.R., Crystal R.G., Besmer P., Lyden D., Moore M.A., Werb Z., Rafii S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002, 109(5):625-637.
44. Hattori K., Heissig B., Tashiro K., Honjo T., Tateno M., Shieh J.H., Hackett N.R., Quitoriano M.S., Crystal R.G., Rafii S., Moore M.A. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001, 97(11):3354-3360.
45. Clarke R., Shipley M., Lewington S., Youngman L., Collins R., Marmot M., Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am. J. Epidemiol. 1999, 150:341-353.